The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028


  • Despite their affordable stock prices, these companies offer massive growth potential and value opportunities.
  • Cardiff Oncology (CRDF): Focuses on novel cancer treatments.
  • BTCS (BTCS): Has transitioned to profitability through a focus on blockchain technology. 
  • Regulus (RGLS): Boasts a solid financial standing.
Cheap Stocks to Buy - The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028

Source: Shutterstock

Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield significant gains.

To begin with, using creative methods to solve unmet medical needs in cancer, the first one has become a leader in the biotechnology industry. The company’s lead product can potentially improve cancer patients’ therapy results by targeting pathways linked to tumor development and progression.

The second stock on our list has significantly moved toward profitability and income diversification. It operates in the fields of blockchain and information technology.

Finally, the third cheap stock to buy is a biotechnology company. It stands out in the industry for its strong positioning and sharp moves to attain long-term leads. The business may progress its pipeline and create value if it has a sizable cash position and a longer runway.

Cardiff Oncology (CRDF)

A scientist holds a test tube while it is in a container
Source: Shutterstock

Cardiff Oncology (NASDAQ:CRDF) discovered a new way that its drug onvansertib works. Specifically, the new method directly reduces the activity of HIF1 alpha, a protein involved in cancer growth. Alongside bev, another cancer medication, the two drugs are more effective in stopping tumor growth.

Cardiff Oncology showed adaptability in its decision to discontinue its ONSEMBLE study, which explored onvansertib for cancer treatment as a secondary or follow-up treatment. Instead, the company is now concentrating on using onvansertib in a first-line setting, referring to the fact that this will be the initial therapy given to patients.

This decision comes with promising data trickling in from Phase 1b/2 clinical trials. In moving toward first-line treatment, Cardiff Oncology aims to unlock more of onvansertib’s potential to benefit a greater number of patients.

Finally, as of 2023, Cardiff Oncology held nearly $75 million in cash, indicating a robust standing. Overall, the business has enough cash to continue current clinical trials with a predicted cash runway into Q3 2025.


An image of a hand holding a cell phone with several visualizations of digital building blocks floating above it. representing sto platforms
Source: Marko Aliaksandr/

BTCS (NASDAQ:BTCS) launched StakeSeeker and Builder+ and is developing ChainQ, among other efforts, to diversify and increase its revenue streams. With the launch of StakeSeeker, a platform for staking as a service and crypto analytics, BTCS demonstrates its efforts to improve income diversification by generating fee-based revenue from asset rewards.

Moreover, Builder+ optimizes block creation and transaction processing, building on to BTCS’ Ethereum (ETH-USD) blockchain infrastructure operations. The work on ChainQ, an AI-powered blockchain data and analytics platform, demonstrates its dedication to offering easily available on-chain information. Thus, ChainQ may provide thorough insights by utilizing AI technology, meeting the increasing demand for blockchain data analytics.

BTCS’s net income in 2023 was greatly improved from last year when the company reported a large deficit. The company reached the breakeven point on the bottom line by the end of 2023, with a net income of $7.8 million or 55 cents per share.

Regulus (RGLS)

Pipette adding fluid to one of several test tubes; biotech NVTA Stock
Source: motorolka /

To fund its expansion, Regulus (NASDAQ:RGLS) has a strong cash position and a long cash runway. Regulus has the liquidity to finance its operations and strategic ambitions with $23.8 million in cash. Thus, Regulus has the capacity to carry out its business strategy without needing urgent funding through 2026.

Furthermore, a $100 million private placement adds massive capital to Regulus’s resources. The size of the funding reflects market confidence in its growth prospects and possible returns on investment.

Regulus’s attempts to increase its performance in line with analysts expectations are reflected in the improvement in loss-per-share metrics from $1.86 in 2022 to $1.58 in 2023.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks.

Read More: Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.

Article printed from InvestorPlace Media,

©2024 InvestorPlace Media, LLC